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•   Can scientists promise anonymity 
of research participants when 
whole sequences data and 
phenotypic data are being used 
for research purposes?
•   Should participants be fed back 
individual findings?
•   Are national research governance 
systems adequate to cope with 
global data sharing?
•   What innovative IT solutions can be 
brought into this field to address 
these challenges and further 
promote data sharing?
Oxford academic Jane Kaye, 
who organised the conference 
and chairs the Centre for Health, 
Law, and Emerging Technologies 
(HeLEX), is working towards a ‘good 
practice’ guide for the sensitive fields 
surrounding genomics, biobanks, and 
data sharing, reconciling the interests 
of researchers and study participants, 
without unduly hindering research. 
Bioethicists working closely 
with a research project known as 
MalariaGEN (Malaria Genomic 
Epidemiology Network) have 
already developed procedures for 
the controlled access to genomic 
data in studies involving vulnerable 
participants, where the notion 
of informed consent is proving 
problematic. 
As malaria mainly affects sub-
Saharan Africa, genomic studies of 
malaria susceptibility necessarily involve 
DNA samples from individuals with 
limited experience or understanding of 
medical research, who might be unable 
to comprehend what might happen with 
their genetic information once it became 
publicly accessible. 
“Because we are aware of the limits 
of consent in such cases, we have 
decided not to release data without 
regulation,” explains Jantina de Vries, 
one of the bioethicists involved in the 
project. In close consultation between 
researchers, ethics committees, 
funding bodies and others, MalariaGEN 
set up a dedicated review panel to 
control access to the genomic data 
generated by the project, the IDAC 
(Independent Data Access Committee). 
The six members of IDAC, all experts in 
relevant disciplines, review all requests 
for access to MalariaGEN data. An 
application form for people interested in 
the data is to be found online, and they 
will have to justify their request with a 
description of their research interest, 
typically about a paragraph or two long. 
MalariaGEN’s data release policy 
also includes the option of delaying 
access for nine months after the date 
when the researchers who created 
the data first had access to it, in order 
to protect the emerging capacity of 
African researchers. 
Some other researchers and 
institutions appear to think that this 
much protection is unnecessary. “This 
area is currently open to debate,” 
admits de Vries. There are many 
prominent genomics researchers 
and research funders who argue 
that unrestricted open access to 
genomic data — with consent 
taken to imply that the DNA donors 
understand the full implications of 
their participation — is the best way 
to promote scientific progress in the 
pursuit of better understanding of 
serious diseases. The bioethicists 
working with MalariaGEN however 
believe that a managed approach to 
data-release is a more sustainable and 
appropriate approach to the promotion 
of science in a global context. 
“We see our approach as a 
contribution to the debate,” says 
de Vries. “It shows that such research 
can be done in an ethical way.” 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web page 
at www.michaelgross.co.uk
A genetically modified salmon is under 
consideration by the US Food and 
Drugs Administration (FDA) which 
could sanction the first such modified 
animal for human consumption. They 
announced earlier this month an 
analysis which found the fish safe to eat 
and unlikely to harm the environment.
Atlantic salmon usually do not grow 
in the winter and take three years to 
mature. Aqua Bounty Technologies 
of Waltham, Massachusetts, has 
invested more than 14 years and 
$60 million developing and seeking 
approval of its AquAdvantage salmon, 
which incorporates genetic material 
from a Chinook salmon and a pout 
fish. The company says its fish look 
and taste like non-engineered North 
Atlantic salmon, consume up to 25 
per cent less food and reach market 
weight in half the time.
require that the fish are raised 
on farms inland. But critics are 
concerned. Andrew Good of 
the Atlantic Salmon Federation 
says he wants a thorough risk 
assessment of the GM salmon  
to be conducted to protect wild 
salmon.
A new genetically modified salmon is 
under consideration in the US.  
Nigel Williams reports.
GM salmon loom If the FDA’s Center for Veterinary Medicine approve the fish, Aqua 
Bounty Technologies believe it could 
be in commercial production within a 
year, and available to purchase within 
two years. 
To reduce the risk to the 
environment, any approval will 
Speeding up: A new genetically modified version of the Atlantic salmon here is claimed to 
reach market weight in half the time of conventional fish. (Picture: Photolibrary.)
